| Outcome Measures: |
Primary: Glycosylated Hemoglobin A1c (HbA1c), non-T2D subjects only tested HbA1c at baseline. Of the 71 patients who completed the study, 69 collected HbA1c at both baseline and study endpoint, and 2 subjects did not carry out HbA1c measurement for personal reasons., 12 weeks later | Secondary: Types of Gene Polymorphism, 24 SNPs genetic points of DPP-4, GLP-1 and GLP-1R., Baseline|Change in Blood Glucose, Fasting Blood glucose, the postprandial 0.5-hour,2-hour,3-hour blood glucose were measured at baseline and at study end points, and the difference between baseline and study end points were compared.Participants in "Non-T2DM Group" were not taking Sitagliptin, so their blood glucose were not measured., Basline and 12 weeks later. Fasting, 0.5h, 2h,3h after take 75g glucose orally.|Change in Insulin, Fasting insulin, the postprandial 0.5-hour,2-hour,3-hour insulin were measured at baseline and at study end points, and the difference between baseline and study end points were compared.The changes in fasting insulin, the postprandial 0.5-hour,2-hour,3-hour insulin were compared among patients with different genotypes at baseline and at study end points.Participants in "Non-T2DM Group" were not taking Sitagliptin, so their insulin were not measured., Basline and 12 weeks later. Fasting and 0.5h, 2h,3h after take 75g glucose orally.|Change in C-peptide, Fasting C-peptide, the postprandial 2-hour C-peptide were measured at baseline and at study end points, and the difference between baseline and study end points were compared.The changes in fasting C-peptide, the postprandial 2-hour C-peptide were compared among patients with different genotypes at baseline and at study end points.Participants in "Non-T2DM Group" were not taking Sitagliptin, so their C-peptide were not measured., Basline and 12 weeks later. Fasting and 2h after take 75g glucose orally.
|
